Nasdaq · CIK 0001157601 · PHARMACEUTICAL PREPARATIONS
MADRIGAL PHARMACEUTICALS, INC.
MDGL chart by TradingView
PRICE HISTORY
LIVE · NASDAQMDGL chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $1.0B
- EBITDA
- $-0.3B
- FREE CASH FLOW
- $-0.2B
- EPS
- $-12.85
- GROSS MARGIN
- —
- ROIC
- -38.75%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 36 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
12.2x
-97%12.2x409.6x
⤢
P / BOOK
29.9x
-85%5.7x256.5x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
12.2x
-97%12.2x383.8x
⤢
FCF YIELD (TTM)
-1.32%
+7.9pp-14.38%-1.14%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.4B
+172531%⤢
EBITDA (DERIVED)
$-0.1B
$0.0B⤢
NET INCOME
$-0.1B
$0.0B⤢
EPS (DILUTED)
$-1.99
$1.69⤢
REVENUE GROWTH YOY
71.17%
+171.2pp-100.00%1353.76%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
5.24%
+5782.0pp-10476.87%27.50%
⤢
RETURN ON CAPITAL
-56.86%
+160.1pp-425.72%-38.75%
⤢
RETURN ON EQUITY (TTM)
-62.07%
+206.2pp-1433.57%-13.93%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN-15.46%
NET MARGIN-15.91%
FCF MARGIN5.24%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.0B
+$0.0B⤢
STOCK-BASED COMP
$0.0B
+4256%⤢
CAPITAL EXPENDITURE
$0.0B
+12051%⤢
SHARES OUTSTANDING
0.03B
-31%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.3B
+1031%⤢
TOTAL DEBT
$0.3B
+306%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 104.02%INSIDERS 5.87%OTHER / RETAIL 0.00%545 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.27% | 2.1M | $1.09B | +0.0% |
| Janus Henderson Group PLC | 8.74% | 2.0M | $1.03B | +27.4% |
| RTW Investments LP | 8.63% | 2.0M | $1.02B | +0.0% |
| Avoro Capital Advisors LLC | 7.87% | 1.8M | $927.3M | +0.6% |
| Blackrock Inc. | 6.75% | 1.6M | $795.6M | -5.1% |
| PAULSON & CO. INC. | 6.03% | 1.4M | $710.1M | -18.5% |
| Vanguard Portfolio Management LLC | 3.64% | 841K | $429.0M | NEW |
| Vanguard Capital Management LLC | 3.58% | 827K | $421.9M | NEW |
| Wellington Management Group, LLP | 3.01% | 695K | $354.5M | +50.6% |
| State Street Corporation | 2.64% | 610K | $310.9M | +4.6% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.